The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

145 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to increase the knowledge about psychological processes which may contribute to mental health problems such as depression and anxiety. This study aims to investigate if administering Escitalopram, an antidepressant which increases serotonin levels in parts of the brain, affects how the brain processes emotional information. It is hoped that measuring these changes will increase the understanding of processes involved in mental health problems.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neural Responses and Dysphoria: Modulation by a Pharmacological Probe

NCT01101685

Dysphoria

COMPLETED PHASE4

Serotonin and Motor Plasticity

NCT03162185

Healthy Controls

UNKNOWN PHASE4

The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms

NCT04336228

Obsessive-Compulsive Disorder/High Compulsive Individuals Healthy Individuals

ACTIVE_NOT_RECRUITING PHASE4

Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic

NCT01424384

Depressive Disorder and Anxiety Disorders

COMPLETED PHASE1

Effort and Antidepressant Study Test

NCT06696482

Effort Based Decision Making Prosocial Behavior Apathy

NOT_YET_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Control - Escitalopram

Participants took 10mg escitalopram for 2-3 weeks, once daily. Escitalopram was administered in the form of a tablet, manufactured and donated for research by Lundbeck (tablet core: microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, talc, magnesium stearate; tablet coating: hypromellose 6cP, titanium dioxide (E171), macrogol 6000). Exact length of administration was dependent on participants' availability to attend their second scan.

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

Participants received 2-3 weeks of escitalopram.

Healthy Control - Placebo

Participants took a placebo tablet for 2-3 weeks, once daily. Placebo was administered in the form of a tablet, manufactured and donated for research by Lundbeck and matching the escitalopram tablet given to the other study groups in colour and size. Exact length of administration was dependent on participants' availability to attend their second scan.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.

Anxious Individuals - Escitalopram

Participants took 10mg escitalopram for 2-3 weeks, once daily. Escitalopram was administered in the form of a tablet, manufactured and donated for research by Lundbeck (tablet core: microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, talc, magnesium stearate; tablet coating: hypromellose 6cP, titanium dioxide (E171), macrogol 6000). Exact length of administration was dependent on participants' availability to attend their second scan.

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

Participants received 2-3 weeks of escitalopram.

Anxious Individuals - Placebo

Participants took a placebo tablet for 2-3 weeks, once daily. Placebo was administered in the form of a tablet, manufactured and donated for research by Lundbeck and matching the escitalopram tablet given to the other study groups in colour and size. Exact length of administration was dependent on participants' availability to attend their second scan.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

Participants received 2-3 weeks of escitalopram.

Intervention Type DRUG

Placebo

Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy Controls:

* Fluency in English
* Registration with a UK General Practitioner
* Capacity for consent
* No personal history of long-term medical conditions or psychiatric illness (including substance dependence, assessed with the Mini International Neuropsychiatric Interview)

Anxious Individuals:

* Fluency in English
* Registration with a UK General Practitioner
* Capacity for consent
* Meeting criteria for generalised anxiety disorder, panic disorder and/or agoraphobia (also assessed with the Mini International Neuropsychiatric Interview); permitted comorbid conditions were: major depressive disorder, obsessive-compulsive disorder and/or post-traumatic stress disorder

Exclusion Criteria

Healthy Controls and Anxious Individuals:

* Having consumed alcohol within 12 hours prior to the study
* having used illicit drugs within 3 months prior to the study
* Having had any contraindications to MRI scanning
* Being pregnant or breastfeeding
* Having had impaired or uncorrected vision or hearing

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes